This site requires JavaScript and cookies to be enabled.

Icon: Medication

Convenient,
once-daily dosing1,2

Nonstimulant Qelbree can be tailored to help meet your patient’s needs.

 

Straightforward, easy administration1

Capsule can be taken whole or entire contents can be sprinkled over a spoonful (teaspoon or tablespoon) of soft food (pudding or applesauce). Consume the entire contents of the pudding mixture within 15 minutes or applesauce mixture within 2 hours, without chewing. Do not store for future use.1,2

  • Capsules and their contents should not be cut, crushed, or chewed
  • Can be taken with or without food
  • Dose will depend on response to medication
Qelbree™ (viloxazine extended-release capsules) can be sprinkled over food

Titrate weekly as needed to optimize ADHD symptom control1,2

 

Children 6 to 111

Titration for children: 100mg in week 1; 200mg in week 2; 300mg in week3; 400mg in week 4
Qelbree™ titration chart for children aged 6-11: 100mg week 1, 200mg week 2, 300mg week 3, 400mg week 4

Titrate Qelbree 100 mg/week over 1 to 3 weeks to reach effective dose.1

 

Adolescents 12 to 171

Qelbree™ titration chart for adolescents aged 12-17: 200mg week 1
Qelbree™ titration chart for adolescents aged 12-17: 200mg week 1, 400mg week 2
Arrow Large
Qelbree™ titration chart for adolescents aged 12-17: 200mg week 1, 400mg week 2

Titrate Qelbree 200 mg/week over 1 week as needed to reach effective dose.1

Maximum dose for children and adolescents is 400 mg daily

 

Adults 18 and older2

Titration for adolescents: 200mg in week 1 (starting dose)
Qelbree™ Titration chart for adults aged 18-65: 200mg week 1, 400mg week 2
Qelbree™ Titration chart for adults aged 18-65: 600mg week 3
Arrow Large
Titration for adults: 400mg in week 2
Arrow Large
Titration for adults: 600mg in week 3

Titrate Qelbree 200mg/week over 1-2 weeks as needed to reach an effective dose; maximum dose for adults is 600 mg daily.1

Maximum dose for adults is 600 mg daily

3 strengths allow for flexible dosing1

Qelbree capsules are available in 3 dosage strengths: 100 mg capsules, 150 mg capsules, and 200 mg capsules.1

100mg Qelbree™ (viloxazine extended-release capsules) capsule
150mg Qelbree™ (viloxazine extended-release capsules) capsule
200mg Qelbree™ (viloxazine extended-release capsules) capsule

Capsules shown are not actual size.

Dosing safety information1

  • Severe renal impairment: Initiate Qelbree at 100 mg and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily
Dosing_Interior_Small
Icon: Dosing calendar

Refills without the need for a new prescription every month

Qelbree, a nonstimulant therapy, offers ADHD multi-symptom control across several phase III clinical trials.1,2

You may even be able to prescribe a 90-day supply for more convenience.*

*Subject to any plan restrictions.

You might also be interested in:

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more]Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
2. Data on file, Supernus Pharmaceuticals.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more]Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.